Madina Abdikadyr, the Project Manager of National Company Kazakh Invest, on April 12 met with Ahmad Kilani, the Chairman of the Board of Directors of the Egyptian company EIPICO, to discuss the company’s plans to build a full-cycle biopharmaceutical plant on the territory of Saran industrial zone in Kazakhstan’s Karaganda region. The planned investment volume will be $30 million, Kazakh Invest reported.
The implementation of the project for the production of biosimilars and anticancer drugs in accordance with international GMP standards is expected to create 150-200 permanent jobs. Products for the treatment of oncologic diseases will be supplied to the domestic market and for export.
Madina Abdikadyr assured Egyptian investors of full support, noting that previously, there was no full-cycle pharmaceutical production in Kazakhstan.
EIPICO is Egypt’s largest pharmaceutical manufacturer, with 276 medicines in 25 therapeutic groups. The company’s products are the leader in the Egyptian market, accounting for 21% of the country’s total pharmaceutical exports.
